Curevac boss Franz-Werner Haas wants to promote international cooperation. Photo: AFP / THOMAS KIENZLE
The head of the Tubingen biotech company Curevac is in favor of not letting the patents expire in the fight against Corona, but suspending them for a short time. This allows research to work faster.
Stuttgart – Franz-Werner Haas, the CEO of the Tubingen biotech company Curevac, calls for close international cooperation to promote the further development of a corona vaccine. In addition to sharing study data on the effectiveness of existing vaccines, it also includes the suspension of patents, he told our newspaper. The patents should be granted in principle, but suspended in the pandemic phase. He is following a recommendation of the World Trade Organization (WTO). "We need each other," says Curevac founder Ingmar Hoerr about combating the pandemic. "The board we are drilling is just too thick."